American Investment
America’s Biopharmaceutical Companies Expand and Advance Manufacturing and Research Across the United States
PhRMA members have committed to invest hundreds of billions of dollars to expand their U.S. presence. Learn how member companies are supporting patients, workers and communities around America.
The biopharmaceutical industry is driving economic growth across America
Together, we’re providing jobs for highly-skilled workers and creating new opportunities for Americans, their families and local communities.
The Biopharmaceutical Industry’s Investment in America
Source: TEConomy Partners, LLC. The Economic Impact of the U.S. Biopharmaceutical Industry: 2022 National and State Estimates. February 2024.
$1.6+ trillion in economic output
Contributes substantially to the American economy, totaling more than $1.65 trillion in economic output, which represents 3.6% of all U.S. output.
1,500+ facilities in 48 states
Operates 1,574 facilities across the country that are manufacturing innovative treatments (as of 2022).
5 million high-skilled jobs
Directly employs more than one million workers and supports an additional 3.8 million U.S. jobs indirectly.
111 million students in STEM programs
Supports 37 STEM education programs across the country, providing $180 million in financial support and reaching nearly 111 million students and 183,000 teachers.
Every day, our industry is working to bring treatments and cures to Americans.
More than 1 million employees of U.S. biopharmaceutical companies work every day to research and develop transformative treatments.
Our industry relies on a talented STEM workforce to advance innovation, which is why we’re committed to investing in the next generation of innovators through education programs at universities across the country.
We’re also working hard to develop new life-saving treatments through clinical trials across the country, with over 5,000 active clinical trial sites reaching more than 900,000 Americans.
Protecting American Investment and Leadership in Biopharmaceutical Innovation
Robust, pro-innovation policies are critical to maintaining our country’s leadership and supporting patient access to transformative medicines.
Our Work in Action
To maintain America’s global leadership, we need to support the next generation of innovation in medicine.
